Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

On March 23, 2021 Selexis SA, a JSR Life Sciences company, and Tallac Therapeutics reported that they have signed both a commercial license agreement (CLA) and a service agreement (SA) to advance Tallac’s Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform, which harnesses the power of innate and adaptive immunity to treat cancer (Press release, Selexis
, MAR 23, 2021, View Source [SID1234577050]). Under the agreements, Tallac will employ Selexis’ proprietary SUREtechnology Platform to develop the research cell banks necessary to bring its immunotherapy candidates for the treatment of solid tumors to the clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud to work with Tallac Therapeutics as the company develops new medicines for cancer," said Yemi Onakunle, PhD, MBA, Selexis chief business officer. "Our work with Tallac will allow Selexis to play a role in the advancement of differentiated immunotherapies that are designed to overcome the resistance and lack of response seen in the majority of patients receiving currently available treatments."

Tallac Therapeutics is developing systemically delivered therapeutics with the potential to provide powerful innate and adaptive anti-tumor immunity. The Company’s TRAAC platform currently supports a pipeline of next-generation immunotherapies that have potential for monotherapy and combination approaches across multiple tumor indications.

"As we advance our pipeline of groundbreaking cancer immunotherapies, we chose Selexis as our cell line development partner because of their innovation and scientific expertise, and their proven commitment to the quality, speed, safety and reliability of the technology solutions they provide," said Dr. Hong I. Wan, Tallac Therapeutics president, CEO and co-founder.

Selexis’ modular SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of recombinant proteins and vaccines, providing seamless integration of the development continuum from discovery to commercialization.

NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors

On March 23, 2021 NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, reported the first patient has been dosed in the Phase 2a portion of a Phase 1b/2a clinical trial evaluating NT-I7 (efineptakin alfa), a novel T cell amplifier, in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of patients with relapsed/refractory advanced solid tumors (Press release, NeoImmuneTech, MAR 23, 2021, View Source [SID1234577049]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 2a portion of this study will enroll up to 150 patients and will explore the preliminary anti-tumor activity of the combination therapy both in patients who have been treated with a checkpoint inhibitor (CPI) for triple-negative breast cancer, non-small cell lung cancer, or small cell lung cancer, and CPI-naïve patients with microsatellite stable colorectal cancer or pancreatic cancer.

"We are excited to quickly advance to the Phase 2a portion of this important clinical trial to further evaluate this combination treatment in patients with a variety of advanced solid tumors," said NgocDiep Le, M.D., Ph.D., Executive VP and Chief Medical Officer of NeoImmuneTech. "We have great confidence in the combination of NT-I7, as a T cell amplifier, with CPI therapies like KEYTRUDA to improve clinical outcomes and become a viable treatment option for many cancer patients, with either CPI-responsive or CPI-resistant tumors."

The results of this study will be used to guide further clinical development of this combination in select tumor types.

More information on this trial can be found at www.clinicaltrials.gov, identifier: NCT04332653

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.

About NT-I7

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7, and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and for sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies

On March 23, 2021 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, reported that it advanced its first oncology program into IND-enabling studies and anticipates filing an IND in the second half of 2021 (Press release, Immunome, MAR 23, 2021, View Source [SID1234577048]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The IL-38 target was identified through the interrogation of a B cell sample from a head and neck cancer patient using the Immunome discovery engine. IL-38 appears to function as a novel innate immune checkpoint, secreted by tumors to inhibit myeloid cell activation and dampen innate anti-tumor immunity. A correlation between high IL-38 expression and poor clinical outcomes in lung cancer was noted in a recent published study (Takada et al., PLoS One, 2018).

Purnanand Sarma, PhD, CEO of Immunome, said, "We are very excited to advance our lead oncology program targeting IL-38, a novel innate immune checkpoint that appears to inhibit infiltration and pro-inflammatory activity of innate immune cells. Our analysis of publicly available data (The Cancer Genome Atlas) further confirms that IL-38 is over-expressed in certain tumors with high unmet clinical need, such as carcinomas of the head, neck and lung and that its expression appears to be correlated to reduced infiltration of innate immune cells."

Dr. Anthony Tolcher, MD, FRCPC, medical oncologist and co-founder of NEXT Oncology as well as a member of Immunome’s Scientifc Advisory Board, said, "Agents targeting the innate immune system, specifically myeloid biology, represent novel approaches in the treatment of solid tumors. Immunome’s target, IL-38, appears to play a key role in keeping the tumor microenvironment immunologically unresponsive, and reversing this dampened immunity may lead to favorable treatment modalities, especially in high unmet medical need diseases where it is overexpressed. I am excited to see this agent moving into IND-enabling studies and head towards the clinic."

Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)

On March 23, 2021 mmunicom, Inc., a global biotechnology company pioneering novel "subtractive" immunotherapies, reported that the Immunopheresis LW-02 blood-filtering column, its leading immuno-oncology product with FDA Breakthrough Device status, has received regulatory clearance (CE Mark certification) in Europe for use in adults with advanced, refractory triple negative breast cancer (TNBC) (Press release, Immunicom, MAR 23, 2021, View Source [SID1234577047]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This CE certification, believed to be the first granted to an immunotherapy to address advanced cancers, is a significant milestone in the battle against refractory, metastatic TNBC, an advanced cancer that frequently evades standard treatments and has created an urgent need for new and effective therapies.

"TNBC accounts for up to 20% of breast cancer cases and is much more aggressive and often carries a worse prognosis than other forms of breast cancer. Treatment options for many are limited to chemotherapy, usually providing only short-term benefit and frequently accompanied by serious side effects," said Amir Jafri, Founder and CEO of Immunicom.

In stark contrast to traditional "additive" treatments such as chemotherapy and Immune Checkpoint Inhibitors (ICI’s), which introduce foreign substances into a patient’s body and are often accompanied by adverse side effects, Immunicom’s patented "subtractive" technology is designed to limit treatment-associated adverse effects while removing immune system inhibitors from the blood, energizing the immune system to address the cancer.

"I believe Immunopheresis has the potential to be a universal therapy that we have all been waiting for. Currently we are observing it to be extremely well tolerated and we are seeing some early, promising antitumor activity," explained Dr. Piotr Wysocki, MD, PhD, Department Head of Oncology at the Jagiellonian University – Medical College Hospital in Krakow, Poland and the president of the Polish Society of Oncology.

Subtractive Therapy – Immunopheresis and the LW-02 Column

Immunicom’s innovative Immunopheresis approach uses the LW-02 column to extract specific immune-suppressive cytokines produced by cancer tumors. Selective removal of these targeted cytokines is intended to neutralize cancer’s ability to block a patient’s natural immune defense mechanisms which are significantly compromised in late-stage, metastatic disease and thereby "re-energizes the immune system to aggressively fight cancer." Immunopheresis is a "subtractive therapy", in contrast to drugs that are "additive", subtractive therapy is meant to avoid the side effects, toxicity and negative impact on a patient’s quality of life typical of other cancer treatments.

Immunicom believes that the LW-02 column could be used either in combination with other therapies or as a stand-alone treatment. The LW-02 Immunopheresis column has already received Breakthrough Device Designation for stage IV metastatic cancers from the U.S. Food and Drug Administration (FDA). Immunicom has obtained ISO 13485 certification for its manufacturing and related quality systems.

The LW-02 Immunopheresis column is currently being evaluated in several global oncology trials for multiple cancers, including TNBC, non-small cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma. It is being investigated both as a monotherapy and in combination with low-dose metronomic chemotherapy and the well-known immunotherapy checkpoint inhibitors Opdivo (Bristol-Myers Squibb) and Tecentriq (Roche). These trials are being conducted in collaboration with world-renowned research organizations and thought leaders including:

Poland – at Jagiellonian University of Krakow Hospital, under the direction of Principal Investigator, Professor Piotr Wysocki, MD, PhD; and

Israel – at Sheba Medical Center’s Ella Lemelbaum Institute for Immuno-Oncology (Tel Aviv), under the direction of Dr. Ronnie Shapira, MD and Prof. Gal Markel, MD, PhD; and

Turkey – at Acıbadem Altunizade Hospital (Istanbul), a member of the Acıbadem/IHH Healthcare Group, under the direction of Principal Investigator, Prof. Dr. Gokhan Demir, MD, PhD.

For an overview of how Immunopheresis breakthrough technology works, watch Immunicom’s How it Works video.

Immunopheresis and the LW-02 column is considered an investigational therapy by the U.S. FDA and other regulatory authorities. The clinical efficacy of the LW-02 column has not yet been demonstrated. Clinical investigations evaluating the clinical efficacy of the LW-02 column for TNBC are ongoing.

About Triple Negative Breast Cancer

Triple-negative breast cancer (TNBC) has fewer treatment options than other types of invasive breast cancer. TNBC is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time it is found and is more likely to come back after treatment than other types of breast cancer. TNBC tumors do not express estrogen or progesterone receptors and an excess of the protein called HER2. This means the growth of the cancer is not fueled by the hormones estrogen and progesterone or by the HER2 protein, which limits the effectiveness of hormone therapy or targeted drugs. These cancers tend to be more common in women younger than age 40, those that have what is called a "BRCA1 mutation," and African Americans. TNBC differs from other types of invasive breast cancer in that it grows and spreads faster, has limited treatment options, and is associated with a worse prognosis (outcome).

PhoreMost Closes £33M ($46M) Series B Financing

On March 23, 2021 PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable’ disease targets, reported it has completed an oversubscribed £33m ($46m) Series B investment round (Press release, PhoreMost, MAR 23, 2021, View Source [SID1234577046]). The round was led by BGF, the UK’s most active growth economy investor, and included new investors XtalPi Inc., Astellas Venture Management, Trend Investment Group, and o2h ventures. Existing investors Parkwalk Advisors, Morningside Ventures, and Jonathan Milner also contributed.
The funding will be used to progress PhoreMost’s preclinical ‘Allosteric PLK1’ collaboration with Sentinel Oncology into the clinic in 2022. The programme is initially targeted towards Glioma. PhoreMost will also progress multiple additional internal first-in-class drug discovery programmes across both oncology and ageing therapeutic indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PhoreMost’s SITESEEKER platform can identify the best new therapeutic targets for any chosen disease setting, and rapidly identify how to develop novel drugs to these targets. This has the potential to significantly increase the diversity of novel treatments for cancer and other unmet diseases. Significantly, PhoreMost has recently deployed SITESEEKER towards the identification of novel E3-ligands, the progression of which has the potential to be highly disruptive within the important new targeted protein degradation therapeutic modality space.

Following the investment round, Dr Catherine Beech will assume the Chair of PhoreMost’s Board of Directors, succeeding Dr Jonathan Milner who will stay on the Board as an NED. Catherine joined PhoreMost as Non-Executive Director in February 2020. Also joining the Board are Tim Rea, investor at BGF, Alan Jiang, Chief Strategy Officer of XtalPi, and Neil Pegg representing Morningside Ventures.

PhoreMost raised £11M ($15M) in a series A round in 2018, after which the Company expanded its SITESEEKER capabilities in both target discovery and drug discovery.

Dr Chris Torrance CEO, PhoreMost, commented: "We are thrilled to include this exceptional group of investors in PhoreMost’s Series B funding round. We are grateful for the continued support of existing investors and are delighted to welcome BGF, alongside strategic investors XtalPi with whom we have a highly valued ongoing research collaboration, and Astellas Venture Management.

PhoreMost is at an incredibly exciting phase of development, having made tremendous progress since the Series A funding. Our lead ‘Allosteric PLK1’ asset is well positioned for clinical entry and our SITESEEKER platform has made valuable discoveries within the targeted protein degradation, oncology and ageing fields. This funding now positions PhoreMost well to prosecute asset development across these high value therapeutic areas.

I would like to thank the PhoreMost team and all of our partner organisations for helping us to achieve such excellent progress toward realising our important mission. I also welcome Catherine Beech to the PhoreMost Chair and thank our outgoing Chair Jonathan Milner for his exceptional stewardship over the past five years."

Tim Rea, investor, BGF, said: "The team at BGF has been actively engaged in expanding our support for life sciences companies in the UK and we are excited to join the PhoreMost team on the next phase of their journey. The Company’s SITESEEKER technology is highly differentiated, addressing an important market need in the identification of novel drug sites within targets previously considered undruggable. We have been consistently impressed with the strong and experienced management team, and we believe PhoreMost is now in an ideal position to capitalise on the potential of its lead asset and innovative pipeline."

Dr Catherine Beech, Chair, PhoreMost, said: "Since joining PhoreMost’s Board I have continued to be impressed by the progress the Company has made, both in terms of its own internal programmes as well as with a range of strategic collaborations. I am honoured to be appointed as Chair and look forward to working even more closely with Chris and the team during this exciting time for PhoreMost."

Dr Alan Jiang, CSO of XtalPi, said: "XtalPi and PhoreMost share the same goal of addressing bottleneck challenges in biopharmaceutical research with innovative technologies. We are excited to support PhoreMost in fulfilling its mission and further strengthen the collaboration between our platforms with complementary capabilities. PhoreMost’s expertise in identifying and validating valuable novel targets, combined with XtalPi’s advantage in using AI to discover and design drug molecules for challenging biding sites, will allow us to generate pipeline assets more efficiently, particularly in underserved therapeutic areas, to the ultimate benefit of patients with few or no treatment options."

Alastair Kilgour, Chief Investment Officer, Parkwalk Advisors, said: "PhoreMost’s technology has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited, and therefore improve the lives of millions suffering with untreated conditions. Since our original investment we have been impressed by the whole PhoreMost team, who have gone from strength to strength. It made perfect sense for us to follow on that original investment and help them accelerate, grow, and continue to meet this important challenge."